TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17259186

Group type: EXPERIMENTAL
Intervention: Pamphlet and discussion group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pamphlet group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Discussion group
Number of subjects: 92
Study: 15529389

Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/day for 1 year
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11472323

Group type: EXPERIMENTAL
Intervention: RBC with clarithromycin and metronidazole
Number of subjects: 118

Group type: COMPARATOR
Intervention: RBC with clarithromycin
Number of subjects: 118
Study: 9826048

Group type: EXPERIMENTAL
Intervention: 1 minute interval
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 3 minute interval
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 4 minute interval
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 5 minute interval
Number of subjects: 270

Group type: COMPARATOR
Intervention: 2 minute interval
Number of subjects: 270

Group type: COMPARATOR
Intervention: 10 minute interval
Number of subjects: 270
Study: 10155090

Group type: EXPERIMENTAL
Intervention: c7E3 Fab (0.25 mg/kg bolus and 10 micrograms/min infusion for 12 hours)
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study: 2892729

Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha (Prostin 15M), 0.25 mg every second hour
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonylamide (Nalodor), 0.5 mg every fourth hour
Number of subjects: 592
Study: 1064238

Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation treatment
Number of subjects: 0
Study: 31229533

Group type: EXPERIMENTAL
Intervention: Surgical clipping
Number of subjects: 103

Group type: COMPARATOR
Intervention: Endovascular treatment (coiling)
Number of subjects: 103
Study: 28958437

Group type: EXPERIMENTAL
Intervention: Clobazam 40 mg/d
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Clobazam 160 mg/d
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 280
Study: 25799080

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 364
Study: 22941790

Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96
Study: 21367400

Group type: EXPERIMENTAL
Intervention: Written Emotional Disclosure (WED)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 0
Study: 19375690

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging with fast RNFL thickness protocol
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonfellow pairs of eyes (control)
Number of subjects: 77
Study: 17328944

Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) administered at graded doses (0.2, 0.6, and 2.0 microg/min)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Papaverine (PA) administered at 12 mg
Number of subjects: 39
Study: 14718288

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 30

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 30
Study: 11715357

Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril
Number of subjects: 3577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3577
Study: 9218236

Group type: EXPERIMENTAL
Intervention: Node-link mapping counseling (n = 82)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard counseling (n = 73)
Number of subjects: 155
Study: 8263086

Group type: EXPERIMENTAL
Intervention: Guided imagery/relaxation tape before and during MRI (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 41
Study: 3138131

Group type: EXPERIMENTAL
Intervention: Amiloride (15 mg p.o.)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Maximum urine flow
Number of subjects: 103
Study: 30777713

Group type: EXPERIMENTAL
Intervention: Customized CAD/CAM prostheses (group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stock prostheses (group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 28474588

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 240
Study: 26152693

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue add-on (S3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glaucoma drops (S2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated (S1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mixed group of other glaucoma medications (S2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cosinor amplitudes
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Area under receiver operating curve (AUC)
Number of subjects: 23
Study: 24092827

Group type: EXPERIMENTAL
Intervention: Oral estradiol (1 mg/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.05 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Endurance exercise training with estradiol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Endurance exercise training with placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 36
Study: 21345418

Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behaviour Therapy (CBT‐E), average of 20‐40 individual sessions with a clinical psychologist
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behaviour Therapy (CBT‐E)
Number of subjects: 125
Study: 18603204

Group type: EXPERIMENTAL
Intervention: Selective neck dissection (SND) of levels I through III
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elective treatment of the neck lymphatics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 0
Study: 18543684

Group type: EXPERIMENTAL
Intervention: Systane treatment (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Purified water treatment (Group B)
Number of subjects: 36
Study: 15605331

Group type: EXPERIMENTAL
Intervention: Home exercise program (12-week duration, including hip flexion range of motion exercises, strengthening exercises for bilateral hip flexors, extensors, and abductors, and a daily 30-minute walk)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 53
Study: 11726485

Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy assessment of muscle oxygenation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy young men)
Number of subjects: 26
Study: 9204352

Group type: EXPERIMENTAL
Intervention: iopentol (Imagopaque 300)
Number of subjects: 96

Group type: COMPARATOR
Intervention: diatrizoate (Urografin 292)
Number of subjects: 96

Group type: COMPARATOR
Intervention: iohexol (Omnipaque 300)
Number of subjects: 96
Study: 8260367

Group type: EXPERIMENTAL
Intervention: ECMV3 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 3 courses)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: ECMV6 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 6 courses)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: EI6 (Etoposide and Ifosfamide for 6 courses)
Number of subjects: 458
Study: 3307228

Group type: EXPERIMENTAL
Intervention: Partusisten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 0
Study: 30946851

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Oral agents including sulphonylurea
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Previous episodes of hypoglycemia before Ramadan
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Overall fasting during Ramadan
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HbA1c and weight post Ramadan fasting
Number of subjects: 360
Study: 27626795

Group type: EXPERIMENTAL
Intervention: Low-Intensity Experimental (LI-E)
Number of subjects: 35

Group type: COMPARATOR
Intervention: High-Intensity Control (HI-C)
Number of subjects: 35
Study: 26299164

Group type: EXPERIMENTAL
Intervention: Lactic acid (LAc) treatment in low P diet
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Citric acid (CAc) treatment in low P diet
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lactic acid (LAc) treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Citric acid (CAc) treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Citric acid (CAc) and Lactic acid (LAc) treatments
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 2
Study: 24464531

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Naltrexone (50 mg) and Alprazolam (0.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral d-amphetamine (0, 15, and 30 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naltrexone (0 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alprazolam (0 mg)
Number of subjects: 8
Study: 21948030

Group type: EXPERIMENTAL
Intervention: Short proximal femoral nail antirotation (PFNA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 81
Study: 19554672

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS) administered every 2 weeks for 6 months
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis controlling for significant covariates
Number of subjects: 160
Study: 17342639

Group type: EXPERIMENTAL
Intervention: Human bocavirus detected in children with acute wheezing
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: High viral loads of human bocavirus
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Human bocavirus DNA in serum specimens
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Low viral loads of human bocavirus
Number of subjects: 259
Study: 14982884

Group type: EXPERIMENTAL
Intervention: CHOEP (CHOP plus etoposide 100 mg/m2 days 1-3)
Number of subjects: 710

Group type: COMPARATOR
Intervention: CHOP (standard chemotherapy)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Interval reduction (biweekly regimens)
Number of subjects: 710
Study: 11195894

Group type: EXPERIMENTAL
Intervention: Anger expression (e.g., President Clinton expressing anger about the Monica Lewinsky scandal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sadness expression (e.g., President Clinton expressing sadness about the Monica Lewinsky scandal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger expression by an unknown politician
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger expression by workers in a company
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry job candidate description
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sad job candidate description
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger expressions
Number of subjects: 0
Study: 9625131

Group type: EXPERIMENTAL
Intervention: 500 mg mesalazine b.i.d.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 500 mg mesalazine u.i.d.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 7942050

Group type: EXPERIMENTAL
Intervention: NO concentration at rest
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NO concentration during exercise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NO concentration in first portion of expired tidal volume
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NO concentration in latter expired portion
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Repeated measurements of expired NO
Number of subjects: 27
Study: 3310626

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g suspension every four hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacid (administered every two hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 100
Study: 31866061

Group type: EXPERIMENTAL
Intervention: Periodontal approach
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Extraction of third molars
Number of subjects: 100
Study: 28569132

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Common group
Number of subjects: 52
Study: 28060214

Group type: EXPERIMENTAL
Intervention: Active-PEMF
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham-PEMF
Number of subjects: 72
Study: 25526597

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 32
Study: 23391714

Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam plus metronidazole
Number of subjects: 203

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 203
Study: 19923038

Group type: EXPERIMENTAL
Intervention: 15-30 mg pioglitazone daily (n=21, pioglitazone group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 42
Study: 19946230

Group type: EXPERIMENTAL
Intervention: L-arginine (2 g tid for 3 months)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 68
Study: 17461852

Group type: EXPERIMENTAL
Intervention: Intramuscular ALCAR 500 mg bid for 14 days followed by oral ALCAR 1000 mg bid for 42 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intramuscular ALCAR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral ALCAR
Number of subjects: 90
Study: 12928045

Group type: EXPERIMENTAL
Intervention: Task-cueing conditions (informative cue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No task-cueing conditions (non-informative cue)
Number of subjects: 0
Study: 10877363

Group type: EXPERIMENTAL
Intervention: Additional 1-hour T-piece trial at PSmin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Extubation directly at PSmin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined patient sample
Number of subjects: 36
Study: 9367461

Group type: EXPERIMENTAL
Intervention: Bivalent live attenuated influenza A virus vaccine (CAV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine (TVV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza virus vaccine (TVV) and intranasal placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination vaccine regimen (CAV and TVV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: TVV and intranasal placebo
Number of subjects: 29
Study: 1531826

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3895150

Group type: EXPERIMENTAL
Intervention: Tracheal instillation of surfactant (3 or 4 mL, prepared from calf lung lavage)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no surfactant treatment)
Number of subjects: 72
Study: 31700099

Group type: EXPERIMENTAL
Intervention: Naked condition
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Type B diapers
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal diapers
Number of subjects: 27
Study: 28783969

Group type: EXPERIMENTAL
Intervention: Activated platelet-rich plasma
Number of subjects: 58

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 58
Study: 27540182

Group type: EXPERIMENTAL
Intervention: 2 year multiple‐component intervention including youth and adult leader training, peer‐led interactive activities, tobacco cessation camps, enforcement of Tobacco Control Law
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 14
Study: 25479296

Group type: EXPERIMENTAL
Intervention: Shared-treadmill desk intervention (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual working condition control group (n = 20)
Number of subjects: 41
Study: 22459543

Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg autologous blood (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 mL/kg autologous blood (Group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 2 mL/kg autologous blood (Group C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 1 mL/kg normal saline (Group D)
Number of subjects: 44
Study: 20055345

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 64
Study: 18599575

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1‐mmol/kg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Gadodiamide (0.1‐mmol/kg)
Number of subjects: 113
Study: 15933967

Group type: EXPERIMENTAL
Intervention: Postoperative supplemental oxygen (8 L/min for 6 hours)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Routine care (5 L/min oxygen in PACU, no supplemental oxygen on the ward)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 12647922

Group type: EXPERIMENTAL
Intervention: Progressive strength training programme
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 17
Study: 11071800

Group type: EXPERIMENTAL
Intervention: abciximab with reduced dose reteplase (5+5 U)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: abciximab with reduced dose reteplase (10+5 U)
Number of subjects: 299

Group type: COMPARATOR
Intervention: standard dose reteplase (10+10 U)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: abciximab with reduced dose reteplase (5+5 U or 10+5 U)
Number of subjects: 299
Study: 8979645

Group type: COMPARATOR
Intervention: On-ice training (Grp 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: On-ice training plus cycle ergometer training (Grp 2)
Number of subjects: 15
Study: 1533771

Group type: EXPERIMENTAL
Intervention: Isradipine (5 to 10 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 to 200 mg/day)
Number of subjects: 26
Study: 3924480

Group type: EXPERIMENTAL
Intervention: Glucose TPN (2550 kcal/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lipid TPN (3000 kcal/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (255 kcal/day)
Number of subjects: 6
Study: 31141081

Group type: EXPERIMENTAL
Intervention: Optimized calorie and high protein nutrition therapy (2.0 to 2.2g/kg/day protein)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard nutrition care (25kcal/kg/day calories and 1.4 to 1.5g/kg/day protein)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Optimized calorie and high protein nutrition therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard nutrition care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 30543657

Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur recombinant, live, attenuated, tetravalent vaccine (CYD‐TDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 26577417

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 466
Study: 25297613

Group type: COMPARATOR
Intervention: Dietary fiber materials (DFMs) including polydextrose, partially hydrolysed guar gum, resistant maltodextrin, partially hydrolysed alginate, glucomannan, heat‐moisture treatment, high‐amylose cornstarch, cellulose
Number of subjects: 0
Study: 22314538

Group type: EXPERIMENTAL
Intervention: Artesunate-sulfadoxine-pyrimethamine (AS-SP)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AM-LF)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (AS-MQ)
Number of subjects: 157
Study: 20530317

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg/d
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study: 18057563

Group type: EXPERIMENTAL
Intervention: Evaluation framework composed of ten quality criteria
Number of subjects: 40

Group type: COMPARATOR
Intervention: No evaluation framework
Number of subjects: 40
Study: 15651575

Group type: EXPERIMENTAL
Intervention: Electrocardiographic electrodes after degradation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Increased electrode impedance
Number of subjects: 12
Study: 11544433

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% glucose (placebo group)
Number of subjects: 10
Study: 9164520

Group type: EXPERIMENTAL
Intervention: Endoscopic Injection Sclerotherapy (EIS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Combined therapy (Endoscopic Variceal Ligation + EIS)
Number of subjects: 61
Study: 7970945

Group type: EXPERIMENTAL
Intervention: Rhesus-human reassortant tetravalent oral rotavirus vaccine (4 x 10^4 plaque-forming units)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 3556051

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Salbutamol from metered-dose inhaler (MDI)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both delivery systems (nebulizer and MDI)
Number of subjects: 19
Study: 1978667

Group type: EXPERIMENTAL
Intervention: Flumazenil (20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1125653

Group type: EXPERIMENTAL
Intervention: Plasma immunoreactive beta‐melanocyte stimulating hormone (beta‐MSH) concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Severity of renal failure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Degree of pigmentation
Number of subjects: 0
Study: 31784217

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-label ivacaftor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0